[Retracted] Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study

Table 3

Hazard ratios for DFS prediction in univariate and multivariate analyses.

	Univariate			Multivariate
	HR	95% CI	value	HR	95% CI	value
Age (year)			0.731			0.917
≤35	1.000			1.000
>35	0.809	0.242–2.707		0.926	0.216–3.966
Menopausal status			0.433			0.128
Premenopausal	1.000			1.000
Postmenopausal	0.726	0.326–1.616		0.475	0.182–1.238
cT stage			0.004			0.006
cT1–2	1.000			1.000
cT3–4	3.166	1.433–6.995		3.801	1.460–9.894
cN stage			0.559			0.242
cN0	1.000			1.000
cN1–3	1.265	0.576–2.776		0.545	0.197–1.509
Grade			0.090			0.041
G1–2	1.000			1.000
G3	3.488	0.822–14.800		5.165	1.069–24.959
HR			0.056			0.927
Positive	1.000			1.000
Negative	2.466	0.977–6.127		0.903	0.101–8.084
Ki-67			0.981			0.607
>30%	1.000			1.000
≤30%	1.009	0.458–2.227		1.257	0.526–3.007
Molecular subtype			0.014			0.244
Luminal B/HER2+	1.000			1.000
Nonluminal/HER2+	2.988	1.248–7.155		3.559	0.421–30.056
Trastuzumab			0.047			0.190
Yes	1.000			1.000
No	2.961	1.015–8.632		2.218	0.674–7.297
Strict pCR			0.055			0.062
Yes	1.000			1.000
No	7.065	0.955–52.241		0.144	0.019–1.101
Lymph node involved			0.024			0.074
0	1.000			1.000
1–3	1.888	0.714–4.992		1.996	0.639–6.237
≥4	5.296	1.688–16.612		4.855	1.240–19.004
Endocrine therapy			0.181			0.259
TAM	1.000			1.000
AI	1.852	0.522–6.563		3.238	0.783–13.398
No	2.765	0.917–8.342		2.261	0.585–8.737